Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion

L. D. Van de Kar, S. A. Lorens, Janice H. Urban, Cynthia Bethea

    Research output: Contribution to journalArticle

    69 Citations (Scopus)

    Abstract

    The present study was undertaken to determine the involvement of serotonergic 5-HT1 and 5-HT2 receptor subtypes in stimulation of the secretion of prolactin. Several 5-HT agonists were administered, in a dose-response fashion, to conscious rats and the effect on the levels of prolactin in plasma was measured. The 5-HT1A + 5-HT1B agonist RU 24969 (5-methoxy-3[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole succinate) and the 5-HT1 + 5-HT2 agonist MK-212 (6-chloro-2-[1-piperazinyl]pirazine) increased levels of prolactin in plasma in a dose-dependent manner. In contrast, the selective 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) and ipsapirone (2-[4-{4-(2-pyrimidinyl)-1-piperazinyl} butyl]-1,2-benzisothiazol-3-(2H)one-1,1-dioxidehydrochloride) did not increase levels of prolactin in plasma at any dose. The 5-HT-releasing drug, fenfluramine, also increased the concentration of prolactin in plasma. Pretreatment with the selective 5-HT2 antagonist, LY53857 (6-methyl-1-[1-methylethyl]ergoline-8-carboxylic acid, 2-hydroxy-1-methyl propyl ester (Z)-2-butenedioate [1:1]), did not significantly diminish an increase in levels of prolactin in plasma, induced by injection of fenfluramine. The antagonist LY53857 inhibited, but did not block the MK-212- and RU 24969-induced increase in the levels of prolactin in plasma. By deduction, these data suggest that 5-HT1B receptors, or as yet undefined 5-HT receptor subtypes may be involved in the stimulation of the secretion of prolactin by endogenously released 5-HT, and that 5-HT2 receptors may play a minor role in the serotonergic regulation of the secretion of prolactin.

    Original languageEnglish (US)
    Pages (from-to)299-305
    Number of pages7
    JournalNeuropharmacology
    Volume28
    Issue number3
    DOIs
    StatePublished - 1989

    Fingerprint

    Serotonin 5-HT2 Receptor Antagonists
    Serotonin Receptor Agonists
    Prolactin
    Serotonin
    LY 53857
    Serotonin 5-HT1 Receptor Agonists
    Fenfluramine
    8-Hydroxy-2-(di-n-propylamino)tetralin
    Ergolines
    Serotonin 5-HT1 Receptors
    Serotonin 5-HT2 Receptor Agonists
    Receptor, Serotonin, 5-HT1B
    Serotonin Receptors
    Succinic Acid
    Carboxylic Acids
    Esters
    Injections

    Keywords

    • 5-HT and 5-HT receptors
    • 5-HT agonists
    • 5-HT antagonist
    • fenfluramine
    • prolactin
    • serotonin

    ASJC Scopus subject areas

    • Cellular and Molecular Neuroscience
    • Drug Discovery
    • Pharmacology

    Cite this

    Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion. / Van de Kar, L. D.; Lorens, S. A.; Urban, Janice H.; Bethea, Cynthia.

    In: Neuropharmacology, Vol. 28, No. 3, 1989, p. 299-305.

    Research output: Contribution to journalArticle

    Van de Kar, L. D. ; Lorens, S. A. ; Urban, Janice H. ; Bethea, Cynthia. / Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion. In: Neuropharmacology. 1989 ; Vol. 28, No. 3. pp. 299-305.
    @article{c5bdbc876dc144f68c1bc41b0b750622,
    title = "Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion",
    abstract = "The present study was undertaken to determine the involvement of serotonergic 5-HT1 and 5-HT2 receptor subtypes in stimulation of the secretion of prolactin. Several 5-HT agonists were administered, in a dose-response fashion, to conscious rats and the effect on the levels of prolactin in plasma was measured. The 5-HT1A + 5-HT1B agonist RU 24969 (5-methoxy-3[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole succinate) and the 5-HT1 + 5-HT2 agonist MK-212 (6-chloro-2-[1-piperazinyl]pirazine) increased levels of prolactin in plasma in a dose-dependent manner. In contrast, the selective 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) and ipsapirone (2-[4-{4-(2-pyrimidinyl)-1-piperazinyl} butyl]-1,2-benzisothiazol-3-(2H)one-1,1-dioxidehydrochloride) did not increase levels of prolactin in plasma at any dose. The 5-HT-releasing drug, fenfluramine, also increased the concentration of prolactin in plasma. Pretreatment with the selective 5-HT2 antagonist, LY53857 (6-methyl-1-[1-methylethyl]ergoline-8-carboxylic acid, 2-hydroxy-1-methyl propyl ester (Z)-2-butenedioate [1:1]), did not significantly diminish an increase in levels of prolactin in plasma, induced by injection of fenfluramine. The antagonist LY53857 inhibited, but did not block the MK-212- and RU 24969-induced increase in the levels of prolactin in plasma. By deduction, these data suggest that 5-HT1B receptors, or as yet undefined 5-HT receptor subtypes may be involved in the stimulation of the secretion of prolactin by endogenously released 5-HT, and that 5-HT2 receptors may play a minor role in the serotonergic regulation of the secretion of prolactin.",
    keywords = "5-HT and 5-HT receptors, 5-HT agonists, 5-HT antagonist, fenfluramine, prolactin, serotonin",
    author = "{Van de Kar}, {L. D.} and Lorens, {S. A.} and Urban, {Janice H.} and Cynthia Bethea",
    year = "1989",
    doi = "10.1016/0028-3908(89)90107-X",
    language = "English (US)",
    volume = "28",
    pages = "299--305",
    journal = "Neuropharmacology",
    issn = "0028-3908",
    publisher = "Elsevier Limited",
    number = "3",

    }

    TY - JOUR

    T1 - Effect of selective serotonin (5-HT) agonists and 5-HT2 antagonist on prolactin secretion

    AU - Van de Kar, L. D.

    AU - Lorens, S. A.

    AU - Urban, Janice H.

    AU - Bethea, Cynthia

    PY - 1989

    Y1 - 1989

    N2 - The present study was undertaken to determine the involvement of serotonergic 5-HT1 and 5-HT2 receptor subtypes in stimulation of the secretion of prolactin. Several 5-HT agonists were administered, in a dose-response fashion, to conscious rats and the effect on the levels of prolactin in plasma was measured. The 5-HT1A + 5-HT1B agonist RU 24969 (5-methoxy-3[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole succinate) and the 5-HT1 + 5-HT2 agonist MK-212 (6-chloro-2-[1-piperazinyl]pirazine) increased levels of prolactin in plasma in a dose-dependent manner. In contrast, the selective 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) and ipsapirone (2-[4-{4-(2-pyrimidinyl)-1-piperazinyl} butyl]-1,2-benzisothiazol-3-(2H)one-1,1-dioxidehydrochloride) did not increase levels of prolactin in plasma at any dose. The 5-HT-releasing drug, fenfluramine, also increased the concentration of prolactin in plasma. Pretreatment with the selective 5-HT2 antagonist, LY53857 (6-methyl-1-[1-methylethyl]ergoline-8-carboxylic acid, 2-hydroxy-1-methyl propyl ester (Z)-2-butenedioate [1:1]), did not significantly diminish an increase in levels of prolactin in plasma, induced by injection of fenfluramine. The antagonist LY53857 inhibited, but did not block the MK-212- and RU 24969-induced increase in the levels of prolactin in plasma. By deduction, these data suggest that 5-HT1B receptors, or as yet undefined 5-HT receptor subtypes may be involved in the stimulation of the secretion of prolactin by endogenously released 5-HT, and that 5-HT2 receptors may play a minor role in the serotonergic regulation of the secretion of prolactin.

    AB - The present study was undertaken to determine the involvement of serotonergic 5-HT1 and 5-HT2 receptor subtypes in stimulation of the secretion of prolactin. Several 5-HT agonists were administered, in a dose-response fashion, to conscious rats and the effect on the levels of prolactin in plasma was measured. The 5-HT1A + 5-HT1B agonist RU 24969 (5-methoxy-3[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole succinate) and the 5-HT1 + 5-HT2 agonist MK-212 (6-chloro-2-[1-piperazinyl]pirazine) increased levels of prolactin in plasma in a dose-dependent manner. In contrast, the selective 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-[di-n-propylamino]tetralin) and ipsapirone (2-[4-{4-(2-pyrimidinyl)-1-piperazinyl} butyl]-1,2-benzisothiazol-3-(2H)one-1,1-dioxidehydrochloride) did not increase levels of prolactin in plasma at any dose. The 5-HT-releasing drug, fenfluramine, also increased the concentration of prolactin in plasma. Pretreatment with the selective 5-HT2 antagonist, LY53857 (6-methyl-1-[1-methylethyl]ergoline-8-carboxylic acid, 2-hydroxy-1-methyl propyl ester (Z)-2-butenedioate [1:1]), did not significantly diminish an increase in levels of prolactin in plasma, induced by injection of fenfluramine. The antagonist LY53857 inhibited, but did not block the MK-212- and RU 24969-induced increase in the levels of prolactin in plasma. By deduction, these data suggest that 5-HT1B receptors, or as yet undefined 5-HT receptor subtypes may be involved in the stimulation of the secretion of prolactin by endogenously released 5-HT, and that 5-HT2 receptors may play a minor role in the serotonergic regulation of the secretion of prolactin.

    KW - 5-HT and 5-HT receptors

    KW - 5-HT agonists

    KW - 5-HT antagonist

    KW - fenfluramine

    KW - prolactin

    KW - serotonin

    UR - http://www.scopus.com/inward/record.url?scp=0024602763&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0024602763&partnerID=8YFLogxK

    U2 - 10.1016/0028-3908(89)90107-X

    DO - 10.1016/0028-3908(89)90107-X

    M3 - Article

    C2 - 2524677

    AN - SCOPUS:0024602763

    VL - 28

    SP - 299

    EP - 305

    JO - Neuropharmacology

    JF - Neuropharmacology

    SN - 0028-3908

    IS - 3

    ER -